A5101430383- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Cancer Mechanisms and Therapy
- Nanoplatforms for cancer theranostics
- Photodynamic Therapy Research Studies
- Hydrogels: synthesis, properties, applications
- Porphyrin and Phthalocyanine Chemistry
- Synthesis and biological activity
- Cancer, Hypoxia, and Metabolism
- Neuroendocrine Tumor Research Advances
- Testicular diseases and treatments
- MRI in cancer diagnosis
- Synthesis and properties of polymers
- Angiogenesis and VEGF in Cancer
- Lung Cancer Research Studies
- Click Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Melanoma and MAPK Pathways
- Adenosine and Purinergic Signaling
- Peptidase Inhibition and Analysis
- Neuroscience and Neuropharmacology Research
- Cancer-related gene regulation
- Advanced Polymer Synthesis and Characterization
- Prostate Cancer Treatment and Research
- Cancer, Stress, Anesthesia, and Immune Response
Freie Universität Berlin
1998-2025
Charité - Universitätsmedizin Berlin
2014-2025
Humboldt-Universität zu Berlin
2017-2025
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2019
Czech Academy of Sciences, Institute of Physiology
2015
German Centre for Cardiovascular Research
2010
Zero to Three
2002-2005
MSB Medical School Berlin
2003
University of California, San Francisco
1998
Relative to normal tissues, tumor microcirculation exhibits high structural and functional heterogeneity leading hypoxic regions impairing treatment efficacy. Here, computational simulations of blood vessel adaptation are used explore the hypothesis that abnormal adaptive responses local hemodynamic metabolic stimuli contribute aberrant morphological characteristics microcirculation. Topology, vascular diameter, length, red cell velocity mesenteric networks were recorded by intravital...
Survivin, a new member of the family apoptosis inhibitors, is expressed almost exclusively in proliferating cells, above all cancers. Subcellular localisation and prognostic implications survivin protein have not yet been determined oesophageal squamous cell carcinoma. The survival 84 patients with carcinomas was correlated extent immunohistochemical expression tumour nuclei. Tumours were scored positive when >5% cells stained positive. Patients followed up for at least 5 years or until...
The peripheral benzodiazepine receptor (PBR) has been implicated in growth control of various tumour models. Although colorectal cancers were found to overexpress PBR, the functional role PBR cancer not addressed date. Using primary cell cultures human and carcinoma lines HT29, LS174T, Colo320 DM we studied involvement apoptosis cancers. Both mRNA protein expression detected by RT-PCR flow cytometry. confocal laser scanning microscopy immunohistochemistry was localized mitochondria. specific...
Background/Objectives: New drugs are required for the treatment of liver cancers and protozoal parasite infections. Analogs known anticancer active antileishmanial 2′,4′,6′-trimethoxychalcone SU086 were prepared investigated. Methods: The chalcones according to Claisen–Schmidt condensation protocol analyzed. They tested activity against two cancer cell lines (HepG2 HuH-7) parasites (Toxoplasma gondii Leishmania major). Unspecific toxicity expression Hsp90 Hsp70 upon analyzed in cells....
Extracellular ATP is known to inhibit growth of various tumours by activating specific purinergic receptors (P2-receptors). Since the therapy advanced oesophageal cancer unsatisfying, new therapeutic approaches are mandatory. Here, we investigated functional expression and potential antiproliferative effects P2-purinergic in human cells. Prolonged incubation primary cell cultures cancers as well squamous line Kyse-140 with or its stable analogue ATPγS dose-dependently inhibited...
Abstract Esophageal cancer is the most markedly increasing tumor entity in Western countries. Due to very poor 5‐year‐survival, new therapeutic approaches are mandatory. Peripheral benzodiazepine receptors (PBR) have been implicated growth control of various models, but they not studied yet esophageal cancer. We used cell lines and primary cultures human cancers evaluated (i) expression localization PBR; (ii) PBR‐ligand‐induced inhibition growth; (iii) induction apoptosis; (iv) alterations...
Gastrointestinal neuroendocrine tumours (NET) represent a heterogeneous tumour entity. The anti-neoplastic therapy of advanced NET disease is still unsatisfactory and innovative therapeutic approaches are needed. As frequently express insulin-like growth factors (IGFs) their receptors (IGFR), known to promote survival, oncogenic transformation, spreading, the inhibition IGF/IGF-receptor system may offer possibilities for novel targeted treatment strategies NET. Here, we studied effects an...
Treatment options of advanced neuroendocrine tumors (NETs) are unsatisfactory. Hence, innovative therapeutic approaches urgently needed. Inhibition histone deacetylases (HDACs) is a promising new approach in cancer therapy. While several HDAC inhibitors have already entered clinical trials, the effect inhibition on NET has not been investigated. Therefore, we evaluated antineoplastic effects three different inhibitors, trichostatin A (TSA), sodium butyrate (NaB), and MS-275, growth apoptosis...
Decades ago, the viral myeloblastosis oncogene v -myb was identified as a gene responsible for development of avian leukemia. However, relevance MYB proteins human cancer diseases, in particular solid tumors, remained basically unrecognized very long time. The family transcription factors comprises (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed several cancers associated with progression resistance to anticancer drugs. In addition overexpression, presence activated...
Abstract Esophageal cancer is the sixth most common cause of cancer‐related death worldwide. Because very poor 5‐year survival new therapeutic approaches are mandatory. Erlotinib (Tarceva™), an inhibitor epidermal growth factor receptor tyrosine kinase (EGFR‐TK), potently suppresses various tumors but its effect on esophageal carcinoma, known to express EGFR, remains unexplored. We therefore studied antineoplastic potency erlotinib in human cells. induced inhibition squamous cell carcinoma...